Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: simpleton_one12 who wrote (9982)	3/20/2007 6:21:13 PM
From: rkrw	Read Replies (1) of 10280

I think it comes down to * lunesta sales not getting the traction hoped for in light of aggressive marketing * xopenex pricing concerns * xopenex generics risk(I expect patents to be upheld) * Worries about ambien going generic in a couple of months * new drug brovana not given much credit, would be a big bonus if it sells well * price may have been inflated from takeover expectations. But on the bright side they'll have a new and imo better suited ceo starting in 5 months. They have a huge sales force and a lot of potential to leverage it. They've never done an inlicense and have done nothing ex-US. So there should be room for improvement.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next